EKSO Ekso Bionics Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EKSO

Price (delayed)

$1.31

Market cap

$23.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.97

Enterprise value

$21.85M

Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Founded in 2005, Ekso ...

Highlights
The gross profit rose by 29% year-on-year
EKSO's EPS is up by 14% year-on-year and by 12% since the previous quarter
Ekso Bionics Holdings's equity has decreased by 34% YoY but it has increased by 11% QoQ
Ekso Bionics Holdings's revenue has increased by 24% YoY but it has decreased by 2% from the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://eksobionics.com
Peers: STAA BIOL IART TNDM

Key stats

What are the main financial stats of EKSO
Market
Shares outstanding
18.17M
Market cap
$23.81M
Enterprise value
$21.85M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.67
Price to sales (P/S)
1.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.22
Earnings
Revenue
$17.91M
EBIT
-$13.99M
EBITDA
-$12.3M
Free cash flow
-$11.43M
Per share
EPS
-$0.97
Free cash flow per share
-$0.66
Book value per share
$0.78
Revenue per share
$1.03
TBVPS
$1.36
Balance sheet
Total assets
$28.96M
Total liabilities
$14.91M
Debt
$6.84M
Equity
$14.05M
Working capital
$13.2M
Liquidity
Debt to equity
0.49
Current ratio
2.81
Quick ratio
1.99
Net debt/EBITDA
0.16
Margins
EBITDA margin
-68.7%
Gross margin
50.4%
Net margin
-79.5%
Operating margin
-77.7%
Efficiency
Return on assets
-46.3%
Return on equity
-95.4%
Return on invested capital
-99%
Return on capital employed
-64.6%
Return on sales
-78.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EKSO stock price

How has the Ekso Bionics Holdings stock price performed over time
Intraday
1.55%
1 week
4.8%
1 month
-9.03%
1 year
-12.08%
YTD
-47.6%
QTD
-3.68%

Financial performance

How have Ekso Bionics Holdings's revenue and profit performed over time
Revenue
$17.91M
Gross profit
$9.03M
Operating income
-$13.92M
Net income
-$14.24M
Gross margin
50.4%
Net margin
-79.5%
The gross profit rose by 29% year-on-year
EKSO's operating margin is up by 29% YoY and by 6% QoQ
Ekso Bionics Holdings's revenue has increased by 24% YoY but it has decreased by 2% from the previous quarter
The net margin is up by 23% YoY and by 4.3% QoQ

Growth

What is Ekso Bionics Holdings's growth rate over time

Valuation

What is Ekso Bionics Holdings stock price valuation
P/E
N/A
P/B
1.67
P/S
1.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.22
EKSO's EPS is up by 14% year-on-year and by 12% since the previous quarter
EKSO's P/B is 49% below its 5-year quarterly average of 3.3 but 4.4% above its last 4 quarters average of 1.6
Ekso Bionics Holdings's equity has decreased by 34% YoY but it has increased by 11% QoQ
The stock's price to sales (P/S) is 60% less than its 5-year quarterly average of 3.2 and 2.3% less than its last 4 quarters average of 1.3
Ekso Bionics Holdings's revenue has increased by 24% YoY but it has decreased by 2% from the previous quarter

Efficiency

How efficient is Ekso Bionics Holdings business performance
The ROE has plunged by 72% YoY and by 5% from the previous quarter
The ROIC has grown by 36% YoY and by 8% from the previous quarter
EKSO's return on sales is up by 23% year-on-year and by 4.2% since the previous quarter
The ROA has contracted by 23% YoY

Dividends

What is EKSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EKSO.

Financial health

How did Ekso Bionics Holdings financials performed over time
Ekso Bionics Holdings's total assets is 94% more than its total liabilities
Ekso Bionics Holdings's total assets has decreased by 22% YoY
The current ratio is up by 13% since the previous quarter but it has declined by 2.8% year-on-year
The debt is 51% lower than the equity
The debt to equity has grown by 40% year-on-year but it has declined by 14% since the previous quarter
Ekso Bionics Holdings's equity has decreased by 34% YoY but it has increased by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.